Polar Capital’s ProQR Therapeutics PRQR Stock Holding History

Polar Capital’s Portfolio PRQR Stock Details PRQR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-100,000	Closed	-$1.58M	–	287
2018 Q4	$1.58M	Hold	100,000	–	–	0.02%	236
2018 Q3	$1.94M	Buy	+100,000	New	+$1.06M	0.02%	251
2016 Q1	–	Sell	-30,000	Closed	-$260K	–	278
2015 Q4	$260K	Sell	30,000 -5,000	-14%	-$57.5K	﹤0.01%	262
2015 Q3	$510K	Buy	+35,000	New	+$586K	0.01%	260
2015 Q2	–	Sell	-16,447	Closed	-$360K	–	299
2015 Q1	$360K	Sell	16,447 -2,307	-12%	-$47.6K	0.01%	273
2014 Q4	$406K	Buy	+18,754	New	+$285K	0.01%	262

Other funds holding PRQR

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

HSBC Holdings London, United Kingdom $192B AUM 27.2% 1-Year Est. Return

Polar Capital's PRQR Position: Q1 2019 in Review

Polar Capital sold out of ProQR Therapeutics (PRQR) in Q1 2019, closing a stake of 100,000 shares — an estimated $1.58M sold.

Polar Capital first reported a position in PRQR in Q4 2014 and held it in 6 quarters. The position peaked at $1.94M in Q3 2018. 56 funds tracked by Wall St. Rank hold PRQR as of Q1 2019.

Polar Capital reported no remaining ProQR Therapeutics position as of Q1 2019 after selling out during the quarter.
Polar Capital sold 100,000 ProQR Therapeutics shares in Q1 2019, an estimated $1.58M.
Polar Capital first reported a position in ProQR Therapeutics in Q4 2014 and held it in 6 quarters.
Polar Capital's ProQR Therapeutics position peaked at $1.94M in Q3 2018.
56 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q1 2019.

Based on Polar Capital's 13F filing for Q1 2019, filed 15 May 2019.